ARCHIVES

FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion

This article is from The Cancer Letter archive.

Vol. 18 No. 01 | January 3, 1992

Download PDF Visit The Full Archive

Related Articles

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

April 13, 2007

Nominations sought for NCI consumer liaison group.

January 9, 2004

Tyrosine Kinase Inhibitor Encoraging For NSCLC

July 27, 2001

DCE Board Approves Concepts for More Chemoprevention Projects, NEW RFAs for PV, Anti-Sense RNA Studies

October 31, 1986

In Brief: Holland Retires As Center Director, Replaced By NCI’s Aaronson; Lab Chiefs Leaving NCI

September 24, 1993

House Appropriations Adds $20 Mil. To Bush Request For NCI, Emphasizes Three Cancers

June 28, 1991